Last reviewed · How we verify
NCT07102953
Mindfulness on Creativity
NA trial testing Focused-attention meditation in Active Control in 111 participants. Currently enrolling.
31 August 2025
Quick facts
| Lead sponsor | Zhejiang University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 111 |
| Start date | 19 May 2025 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 August 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Focused-attention meditation
- Open-monitoring meditation
- Audio-listening control
Conditions studied
- Active Control — all drugs for Active Control →
- Focused-attention Meditatioin — all drugs for Focused-attention Meditatioin →
- Open-monitoring Meditation — all drugs for Open-monitoring Meditation →
Sponsor
Zhejiang University
Who can join
Adults 18 to 65, any sex, with Active Control or Focused-attention Meditatioin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Purpose of the Study This clinical trial aims to find out whether a 5-day mindfulness training program can help improve creativity in academic researchers. The study focuses on answering these key questions: Can focused-attention (FA) and open-monitoring (OM) meditation boost creativity in academic researchers? Do FA and OM meditation have different effects on creativity? How does the training affect brain activity (measured by electrical signals)? Researchers will compare the effects of FA and OM meditation with a control group that listens to audio recordings, to see which method-if any-helps improve creativity. What Participants Will Do Join one of three groups: FA meditation, OM meditation, or audio listening (control), and take part in daily practice for 5 days. Come to the research center for testing three times. Keep a daily log of how they engage with the training.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07102953
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Zhejiang University trials
Trials by the same sponsor.
- NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
- NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
- NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
- NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07102953 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
- Last refreshed: 5 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07102953.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing